Hematological Markers in Accessing Clinical Characteristics and Disease Severity in Hospitalized Patients with COVID-19: A Single-Centric Cross-Sectional Study
DOI:
https://doi.org/10.61814/jkahs.v6i2.741Keywords:
Coronavirus infection, Hematological markers, Prognosis, OutcomeAbstract
Background: Coronavirus disease is a respiratory illness caused by coronavirus infection. Considering its capability of involving multiple systems showing diverse clinical patterns with complications and death, its needful to recognize reliable predictors of disease severity so that we can allocate the available healthcare facilities and arrange a prompt clinical intervention. This study aims to identify common easily available hematological markers and correlate the clinical severity and outcome.
Methods: This observational cross-sectional study was done on 110 COVID-19 RT-PCR-positive patients admitted to the Intensive care unit of Devdaha Medical College. Clinical and laboratory values of hematological parameters like Hemoglobin, leucocyte count, platelets, Neutrophil to lymphocyte ratio, platelets to lymphocyte ratio, and, serum ferritin were recorded from hospital records and case files and analysis was done in relation to disease severity and outcome.
Results: Total 110 patients (56 females) were included in this study. The mean age at presentation was 56.5±15.6 years. Fifty-four patients had a chronic disease, the most common were hypertension and diabetes; and complications were high in them (70.38%). The most common complaints were shortness of breath, cough, and fever. Anemia was present in 61.8% of patients, and lymphopenia in 70%. Increased levels of neutrophil to lymphocyte ratio was seen in 93.6% while that of platelets to lymphocyte ratio in 63.64%, and of ferritin in 42.7% of patients. Sixty percent of patients improved with treatment while 11.6% expired during the course of hospital stay. Most of the patients with complications and mortality had deranged hematological markers.
Conclusions: Ferritin levels were statistically significant for assessing mortality outcomes. Other common hematological biomarkers like lymphocyte count, platelet to lymphocyte ratio, and neutrophil to lymphocyte ratio could be used for risk stratification and prediction of disease course, identifying vulnerable patients at an early phase of illness, and managing patients as per need.
References
He F, Deng Y, Li W. Coronavirus disease 2019: What we know? J Med Virol; doi:
https://doi.org/10.1002/jmv.25766.
World Health Organization. Statement on the second meeting of the international health regulations (2005). Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV); 2020. Available from: https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the- international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov. Accessed January 13, 2021.
Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M. BMJ Evid Based Med. 2020;doi: http://dx.doi.org/10.1136/bmjebm-2020-111536.
Russell CD, Parajuli A, Gale HJ, Bulteel NS, Schuetz P, de Jager CPC, et al. The utility of peripheral blood leucocyte ratios as biomarkers in infectious diseases: a systematic review and meta-analysis. J Infect. 2019;78(5):339–48; doi: https://doi.org/10.1016/j.jinf.2019.02.006
Patel KA, Patel B, Parmar RA, Sharma BS, Thacker M, Patel N. A study of hematological parameters in patients with COVID-19 infection at a tertiary care centre. J Pathol Nepal. 2021;11(1):1852–8; doi: https://doi.org/10.3126/jpn.v11i1.31401
Forget P, Khalifa C, Defour J-P, Latinne D, Van Pel M-C, De Kock M. What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Res Notes. 2017;10:1–4. https://doi.org/10.1186/s13104-016-2335-5. (Google Scholar) (PubMed) (Full text)
Wu L, Zou S, Wang C, Tan X, Yu M. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in Chinese Han population from Chaoshan region in South China. BMC Cardiovasc Disord. 2019;19:1–5; doi: https://doi.org/10.1186/s12872-019-1110-7.
Koperdanova M, Cullis JO. Interpreting raised serum ferritin levels. bmj. 2015;351. doi: https://doi.org/10.1136/bmj.h3692.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. doi: 10.1056/NEJMoa2002032.
Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. bmj. 2020;368. doi: https://doi.org/10.1136/bmj.m606.
Yang A-P, Liu J, Tao W, Li H. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020;84:106504. https://doi.org/10.1016/j.intimp.2020.106504.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.
Thakur B, Dubey P, Benitez J, Torres JP, Reddy S, Shokar N, et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci Rep. 2021;11(1):1–13. https://doi.org/10.1038/s41598-021-88130-w.
Jain V, Yuan J-M. Systematic review and meta-analysis of predictive symptoms and comorbidities for severe COVID-19 infection. Medrxiv. 2020; doi: https://doi.org/10.1101/2020.03.15.20035360.
Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833–9; doi: https://doi.org/10.1016/j.jiph.2020.07.014.
He Z, Zhao C, Dong Q, Zhuang H, Song S, Peng G, et al. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis. 2005;9(6):323–30; doi: https://doi.org/10.1016/j.ijid.2004.07.014.
Manal M, Abdelilah E, Mohammed M, Rajae A, Amine BM, Houssam B, et al. Lymphopenia in Covid-19: a single center retrospective study of 589 cases. Ann Med Surg. 2021;69:102816;doi: https://doi.org/10.1016/j.amsu.2021.102816.
Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J intensive care. 2020;8(1):1–10; doi: https://doi.org/10.1186/s40560-020-00453-4.
Agrawal M, Aleynick M, Belabed M, Britton G, Brown M, Casanova-Acebes M, et al. Immunology of COVID-19: current state of the science. 2020; doi: https://doi.org/10.1016/j.immuni.2020.05.002.
Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18(1):1–12; doi: https://doi.org/10.1186/s12967-020-02374-0.
Asrie F, Tekle E, Gelaw Y, Dagnew M, Gelaw A, Negash M, et al. Baseline Thrombocytopenia and Disease Severity Among COVID-19 Patients, Tibebe Ghion Specialized Hospital COVID-19 Treatment Center, Northwest Ethiopia. J Blood Med. 2022;13:315; doi: https://doi.org/10.2147/JBM.S366478.
Guan CS, Lv Z Bin, Yan S, Du YN, Chen H, Wei LG, et al. Imaging features of coronavirus disease 2019 (COVID-19): evaluation on thin-section CT. Acad Radiol. 2020; 27(5):609–13; doi: https://doi.org/10.1016/j.acra.2020.03.002.
Qu R, Ling Y, Zhang Y, Wei L, Chen X, Li X, et al. Platelet‐to‐lymphocyte ratio is associated with prognosis in patients with coronavirus disease‐19. J Med Virol. 2020; 92(9):1533–41; doi: https://doi.org/10.1002/jmv.25767.
Simadibrata DM, Pandhita BAW, Ananta ME, Tango T. Platelet-to-lymphocyte ratio, a novel biomarker to predict the severity of COVID-19 patients: A systematic review and meta-analysis. J intensive Care Soc. 2022; 23(1):20–6; doi: https://journals.sagepub.com/doi/pdf/10.1177/1751143720969587.
Chan AS, Rout A. Use of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in COVID-19. J Clin Med Res. 2020; 12(7):448; doi: https://doi.org/10.14740%2Fjocmr4240.
Kaushal K, Kaur H, Sarma P, Bhattacharyya A, Sharma DJ, Prajapat M, et al. Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis. J Crit Care. 2022; 67: 172-81; doi:https://doi.org/10.1016/j.jcrc.2021.09.023.
Feld J, Tremblay D, Thibaud S, Kessler A, Namangan L. Ferritin levels in patients with COVID‐19: a poor predictor of mortality and hemophagocytic lymphohistiocytosis. Int J Lab Hematol. 2020; 42(6):773–9; doi: https://doi.org/10.1111/ijlh.13309.
Zhou F. Y u T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054–62; doi: https://doi.org/10.1016/S0140-6736(20)30566-3.
Vargas-Vargas M, Cortés-Rojo C. Ferritin levels and COVID-19. Rev Panam Salud Pública. 2020; 44: e72; doi: https://doi.org/10.26633/RPSP.2020.72.
Banchini F, Cattaneo GM, Capelli P. Serum ferritin levels in inflammation: a retrospective comparative analysis between COVID-19 and emergency surgical non-COVID-19 patients. World J Emerg Surg. 2021; 16(1):1–7. https://doi.org/10.1186/s13017-021-00354-3.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Sundar Pandey, Abhinash Pokharel
This work is licensed under a Creative Commons Attribution 4.0 International License.
The author(s) retain the copyright and the full publishing right without restriction under the Creative Commons Attribution 4.0 International License (CC BY 4.0) which allows readers to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) for any purpose, even commercially, provided the work is properly attributed. (https://creativecommons.org/licenses/by/4.0/).
Author(s) grant the non-exclusive publishing right to the Journal of Karnali Academy of Health Sciences (JKAHS). The publishing rights include the rights to publish, reproduce, distribute, include in indexes or search databases or other media in print or online. The JKAHS may require revisions to the manuscript before acceptance for publication or may choose not to publish it based on the judgement of the editors. Further, JKAHS might retract, withdraw, or publish a correction or other notice after publication, if such publication would be inconsistent with the good publication practices and associated guidelines set forth by the COPE (Committee on Publication Ethics) (https://publicationethics.org/core-practices).
More information about the Creative Commons Attribution 4.0 International License can be found in the webpage of Creative Commons (CC) by following the link provided below: https://creativecommons.org/licenses/by/4.0/
